Table 3.
Odd ratios for epithelial ovarian cancer by surgical details of tubal ligation in the New England Case-Control study, 1984-2008.
| Cases (N) | Minimally-adjusteda OR | Multivariate- adjustedb OR | P for Heterogeneityc | P for trend | |
|---|---|---|---|---|---|
| Timing of TL procedure | |||||
| At last delivery | 57 | 0.46(0.33,0.64) | 0.60(0.42,0.84) | 0.02 | |
| After last delivery | 198 | 0.73(0.60,0.89) | 0.93(0.75,1.15) | ||
| Type of last delivery | |||||
| Vaginal | 36 | 0.51(0.34,0.78) | 0.68(0.44,1.05) | 0.31 | |
| C-section | 21 | 0.38(0.23,0.64) | 0.48(0.28,0.82) | ||
| Type of TL procedure | |||||
| Tying | 57 | 0.66(0.47,0.94) | 0.81(0.56,1.16) | 0.87 | |
| Banding | 12 | 0.55(0.27,1.12) | 0.67(0.32,1.42) | ||
| Burning | 45 | 0.60(0.41,0.88) | 0.73(0.49,1.09) | ||
| Age at TL | |||||
| <30 | 62 | 0.63(0.45,0.88) | 0.71(0.50,1.00) | 0.39 | 0.21 |
| 30-34 | 89 | 0.64(0.48,0.84) | 0.83(0.62,1.10) | ||
| 35-39 | 82 | 0.55(0.42,0.73) | 0.75(0.56,1.01) | ||
| 40+ | 56 | 0.81(0.56,1.17) | 1.07(0.73,1.56) | ||
| Years since TL | |||||
| <10 | 36 | 0.51(0.34,0.77) | 0.74(0.48,1.13) | 0.15 | 0.32 |
| 10-20 | 99 | 0.69(0.53,0.91) | 0.92(0.69,1.22) | ||
| 20-30 | 118 | 0.71(0.56,0.92) | 0.88(0.68,1.15) | ||
| 30+ | 36 | 0.47(0.31,0.71) | 0.54(0.35,0.83) | ||
| Year of TL | |||||
| <1970 | 27 | 0.95(0.55,1.64) | 1.13(0.64,1.99) | 0.21 | 0.03 |
| 1970s | 123 | 0.73(0.57,0.93) | 0.92(0.71,1.19) | ||
| 1980s | 108 | 0.58(0.45,0.74) | 0.73(0.56,0.95) | ||
| 1990+ | 31 | 0.44(0.28,0.68) | 0.61(0.39,0.96) |
Model adjusted for age one year prior to enrollment (continuous), study center (MA, NH) and study phase (NECC2-5).
Model adjusted for age one year prior to enrollment (continuous), study center (MA, NH), study phase (NECC2-5), breastfeeding duration (continuous), parity (nulliparous, 1, 2, 3, 4+ live born), OC use (<3 months, 3 months to <1 year, 1 to < 3 years, 3 to <6 years, 6 to <12 years, 12+ years), BMI (<23 kg/m2, 23 to <25 kg/m2, 25 to <30 kg/m2, 30+ kg/m2), smoking status (never, former, current), age at menarche (7 to <12, 12, 13, 14, 15+ years old), postmenopausal hormone (PMH) use (never, ever estrogen, ever estrogen plus progesterone, ever other type of hormone), family history of ovarian cancer or early onset breast cancer, talc use (yes, no), and menopausal status (premenopausal, postmenopausal) and hysterectomy status (never, ever.)
P for heterogeneity was calculated for the multivariate-adjusted models.